Ms Charlene G Halbert, MA | |
5900 S Lake Dr, Cudahy, WI 53110-3171 | |
(414) 489-4072 | |
Not Available |
Full Name | Ms Charlene G Halbert |
---|---|
Gender | Female |
Speciality | Audiologist |
Location | 5900 S Lake Dr, Cudahy, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649387242 | NPI | - | NPPES |
41134100 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | 259-156 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Charlene G Halbert, MA 3301 W Forest Home Ave, Milwaukee, WI 53215-2843 Ph: (414) 647-6326 | Ms Charlene G Halbert, MA 5900 S Lake Dr, Cudahy, WI 53110-3171 Ph: (414) 489-4072 |
News Archive
Dedicated to keeping area physicians ahead of the curve, Marquette General Health System (MGHS) will work with McKesson to deploy electronic health record (EHR) technology designed to help improve patient care throughout Michigan's Upper Peninsula. The region's only tertiary care provider plans to use McKesson's Practice PartnerĀ® EHR, which integrates with the McKesson ParagonĀ® hospital information system (HIS) currently supporting Marquette General Hospital and its 30 owned physician practices.
States are grappling with mental health issues including a redesign of a program in Iowa, increased coverage for the mentally ill in California and a mental health first aid pilot program in Pennsylvania.
Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.
ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.
› Verified 1 days ago